Patients with NSCLC harboring MET exon 14 skipping mutations are sensitive to MET tyrosine kinase inhibitors (TKIs), and a variety of MET TKIs are available [8, 14, 15]. This evidence concerns the gene MET and non-small cell lung carcinoma.